Liquid Biopsy in Glioblastoma

Lorian Ronvaux; Matteo RIVA; An Coosemans; Marielle Herzog; Guillaume ROMMELAERE; Nathalie Donis; Lionel D'HONDT; Jonathan Douxfils

doi:10.3390/cancers14143394

Liquid Biopsy in Glioblastoma

Lorian Ronvaux, Matteo RIVA, An Coosemans, Marielle Herzog , Guillaume ROMMELAERE, Nathalie Donis, Lionel D'HONDT, Jonathan Douxfils

Research output: Contribution to journal › Review article › peer-review

18 Downloads (Pure)

Abstract

Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Despite recent advances in therapy modalities, the overall survival of GBM patients remains poor. GBM diagnosis relies on neuroimaging techniques. However, confirmation via histopathological and molecular analysis is necessary. Given the intrinsic limitations of such techniques, liquid biopsy (mainly via blood samples) emerged as a non-invasive and easy-to-implement alternative that could aid in both the diagnosis and the follow-up of GBM patients. Cancer cells release tumoral content into the bloodstream, such as circulating tumor DNA, circulating microRNAs, circulating tumor cells, extracellular vesicles, or circulating nucleosomes: all these could serve as a marker of GBM. In this narrative review, we discuss the current knowledge, the advantages, and the disadvantages of each circulating biomarker so far proposed.

Original language	English
Article number	3394
Journal	Cancers (Basel)
Volume	14
Issue number	14
DOIs	https://doi.org/10.3390/cancers14143394
Publication status	Published - 13 Jul 2022

Keywords

biomarkers
circulating microRNAs
circulating nucleosomes
circulating tumor cells
circulating tumor DNA
diagnosis
extracellular vesicles
follow-up
glioblastoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers14143394

cancers_14_03394Final published version, 1.96 MBLicence: CC BY

https://www.mdpi.com/2072-6694/14/14/3394

Cite this

@article{1ae45d9a65c44fc094fb675fcf13bc94,

title = "Liquid Biopsy in Glioblastoma",

abstract = "Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Despite recent advances in therapy modalities, the overall survival of GBM patients remains poor. GBM diagnosis relies on neuroimaging techniques. However, confirmation via histopathological and molecular analysis is necessary. Given the intrinsic limitations of such techniques, liquid biopsy (mainly via blood samples) emerged as a non-invasive and easy-to-implement alternative that could aid in both the diagnosis and the follow-up of GBM patients. Cancer cells release tumoral content into the bloodstream, such as circulating tumor DNA, circulating microRNAs, circulating tumor cells, extracellular vesicles, or circulating nucleosomes: all these could serve as a marker of GBM. In this narrative review, we discuss the current knowledge, the advantages, and the disadvantages of each circulating biomarker so far proposed.",

keywords = "biomarkers, circulating microRNAs, circulating nucleosomes, circulating tumor cells, circulating tumor DNA, diagnosis, extracellular vesicles, follow-up, glioblastoma",

author = "Lorian Ronvaux and Matteo RIVA and An Coosemans and Marielle Herzog and Guillaume ROMMELAERE and Nathalie Donis and Lionel D'HONDT and Jonathan Douxfils",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = jul,

day = "13",

doi = "10.3390/cancers14143394",

language = "English",

volume = "14",

journal = "Cancers (Basel)",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "14",

}

TY - JOUR

T1 - Liquid Biopsy in Glioblastoma

AU - Ronvaux, Lorian

AU - RIVA, Matteo

AU - Coosemans, An

AU - Herzog , Marielle

AU - ROMMELAERE, Guillaume

AU - Donis, Nathalie

AU - D'HONDT, Lionel

AU - Douxfils, Jonathan

PY - 2022/7/13

Y1 - 2022/7/13

N2 - Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Despite recent advances in therapy modalities, the overall survival of GBM patients remains poor. GBM diagnosis relies on neuroimaging techniques. However, confirmation via histopathological and molecular analysis is necessary. Given the intrinsic limitations of such techniques, liquid biopsy (mainly via blood samples) emerged as a non-invasive and easy-to-implement alternative that could aid in both the diagnosis and the follow-up of GBM patients. Cancer cells release tumoral content into the bloodstream, such as circulating tumor DNA, circulating microRNAs, circulating tumor cells, extracellular vesicles, or circulating nucleosomes: all these could serve as a marker of GBM. In this narrative review, we discuss the current knowledge, the advantages, and the disadvantages of each circulating biomarker so far proposed.

AB - Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Despite recent advances in therapy modalities, the overall survival of GBM patients remains poor. GBM diagnosis relies on neuroimaging techniques. However, confirmation via histopathological and molecular analysis is necessary. Given the intrinsic limitations of such techniques, liquid biopsy (mainly via blood samples) emerged as a non-invasive and easy-to-implement alternative that could aid in both the diagnosis and the follow-up of GBM patients. Cancer cells release tumoral content into the bloodstream, such as circulating tumor DNA, circulating microRNAs, circulating tumor cells, extracellular vesicles, or circulating nucleosomes: all these could serve as a marker of GBM. In this narrative review, we discuss the current knowledge, the advantages, and the disadvantages of each circulating biomarker so far proposed.

KW - biomarkers

KW - circulating microRNAs

KW - circulating nucleosomes

KW - circulating tumor cells

KW - circulating tumor DNA

KW - diagnosis

KW - extracellular vesicles

KW - follow-up

KW - glioblastoma

UR - http://www.scopus.com/inward/record.url?scp=85136371506&partnerID=8YFLogxK

U2 - 10.3390/cancers14143394

DO - 10.3390/cancers14143394

M3 - Review article

SN - 2072-6694

VL - 14

JO - Cancers (Basel)

JF - Cancers (Basel)

IS - 14

M1 - 3394

ER -

Liquid Biopsy in Glioblastoma

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Clinical Pharmacology Research Group

The GLIOMARKERS project - development of biomarkers for the diagnostic and the prognostic of glioblastoma

Cite this

Liquid Biopsy in Glioblastoma

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Projects

Clinical Pharmacology Research Group

The GLIOMARKERS project - development of biomarkers for the diagnostic and the prognostic of glioblastoma

Cite this